0.018716
0.000000
0.000000
0.000000
0.013926
0.000000
0.000000
0.000000
0.013881
0.00000
0.00000
0.00000
Berg, S.
Bhat, R.
Anderson, M.
Bergh, M.
Brassington, C.
Hellberg, S.
Jerning, E.
Hogdin, K.
Lo-Alfredsson, Y.
Neelissen, J.
Nilsson, Y.
Ormo, M.
Soderman, P.
Stanway, J.
Tucker, J.
von Berg, S.
Weigelt, T.
Xue, Y.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
4
90.00
90.00
90.00
53.430
71.810
72.040
C20 H23 N7 O3 S
441.507
3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL]SULFAMOYL}PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
non-polymer
C2 H4 O
44.053
ACETYL GROUP
non-polymer
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C3 H8 O3
92.094
GLYCEROL
GLYCERIN; PROPANE-1,2,3-TRIOL
non-polymer
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
H2 O
18.015
WATER
non-polymer
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
N
1
N
C
N
2
N
N
N
3
N
C
N
4
N
C
N
5
N
C
N
6
N
N
N
7
N
S
N
8
N
O
N
9
N
O
Y
10
N
C
Y
11
N
C
Y
12
N
C
Y
13
N
C
Y
14
N
C
Y
15
N
C
Y
16
N
C
Y
17
N
C
Y
18
N
N
Y
19
N
C
Y
20
N
C
Y
21
N
N
N
22
N
C
N
23
N
O
N
24
N
N
Y
25
N
C
Y
26
N
C
Y
27
N
C
Y
28
N
C
Y
29
N
N
Y
30
N
C
N
31
N
N
N
32
N
H
N
33
N
H
N
34
N
H
N
35
N
H
N
36
N
H
N
37
N
H
N
38
N
H
N
39
N
H
N
40
N
H
N
41
N
H
N
42
N
H
N
43
N
H
N
44
N
H
N
45
N
H
N
46
N
H
N
47
N
H
N
48
N
H
N
49
N
H
N
50
N
H
N
51
N
H
N
52
N
H
N
53
N
H
N
54
N
H
N
55
N
C
N
56
N
O
N
57
N
C
N
58
N
H
N
59
N
H
N
60
N
H
N
61
N
H
N
62
N
N
N
63
S
C
N
64
N
C
N
65
N
O
N
66
N
C
N
67
N
O
N
68
N
H
N
69
N
H
N
70
N
H
N
71
N
H
N
72
N
H
N
73
N
H
N
74
N
H
N
75
N
N
N
76
S
C
N
77
N
C
N
78
N
O
N
79
N
C
N
80
N
C
N
81
N
C
N
82
N
N
N
83
N
C
N
84
N
N
N
85
N
N
N
86
N
O
N
87
N
H
N
88
N
H
N
89
N
H
N
90
N
H
N
91
N
H
N
92
N
H
N
93
N
H
N
94
N
H
N
95
N
H
N
96
N
H
N
97
N
H
N
98
N
H
N
99
N
H
N
100
N
H
N
101
N
H
N
102
N
N
N
103
S
C
N
104
N
C
N
105
N
O
N
106
N
C
N
107
N
C
N
108
N
O
N
109
N
N
N
110
N
O
N
111
N
H
N
112
N
H
N
113
N
H
N
114
N
H
N
115
N
H
N
116
N
H
N
117
N
H
N
118
N
H
N
119
N
N
N
120
S
C
N
121
N
C
N
122
N
O
N
123
N
C
N
124
N
C
N
125
N
O
N
126
N
O
N
127
N
O
N
128
N
H
N
129
N
H
N
130
N
H
N
131
N
H
N
132
N
H
N
133
N
H
N
134
N
H
N
135
N
N
N
136
R
C
N
137
N
C
N
138
N
O
N
139
N
C
N
140
N
S
N
141
N
O
N
142
N
H
N
143
N
H
N
144
N
H
N
145
N
H
N
146
N
H
N
147
N
H
N
148
N
H
N
149
N
N
N
150
S
C
N
151
N
C
N
152
N
O
N
153
N
C
N
154
N
C
N
155
N
C
N
156
N
O
N
157
N
N
N
158
N
O
N
159
N
H
N
160
N
H
N
161
N
H
N
162
N
H
N
163
N
H
N
164
N
H
N
165
N
H
N
166
N
H
N
167
N
H
N
168
N
H
N
169
N
N
N
170
S
C
N
171
N
C
N
172
N
O
N
173
N
C
N
174
N
C
N
175
N
C
N
176
N
O
N
177
N
O
N
178
N
O
N
179
N
H
N
180
N
H
N
181
N
H
N
182
N
H
N
183
N
H
N
184
N
H
N
185
N
H
N
186
N
H
N
187
N
H
N
188
N
N
N
189
N
C
N
190
N
C
N
191
N
O
N
192
N
O
N
193
N
H
N
194
N
H
N
195
N
H
N
196
N
H
N
197
N
H
N
198
N
C
N
199
N
O
N
200
N
C
N
201
N
O
N
202
N
C
N
203
N
O
N
204
N
H
N
205
N
H
N
206
N
H
N
207
N
H
N
208
N
H
N
209
N
H
N
210
N
H
N
211
N
H
N
212
N
N
N
213
S
C
N
214
N
C
N
215
N
O
N
216
N
C
Y
217
N
C
Y
218
N
N
Y
219
N
C
Y
220
N
C
Y
221
N
N
N
222
N
O
N
223
N
H
N
224
N
H
N
225
N
H
N
226
N
H
N
227
N
H
N
228
N
H
N
229
N
H
N
230
N
H
N
231
N
H
N
232
N
H
N
233
N
O
N
234
N
H
N
235
N
H
N
236
N
N
N
237
S
C
N
238
N
C
N
239
N
O
N
240
S
C
N
241
N
C
N
242
N
C
N
243
N
C
N
244
N
O
N
245
N
H
N
246
N
H
N
247
N
H
N
248
N
H
N
249
N
H
N
250
N
H
N
251
N
H
N
252
N
H
N
253
N
H
N
254
N
H
N
255
N
H
N
256
N
H
N
257
N
H
N
258
N
N
N
259
S
C
N
260
N
C
N
261
N
O
N
262
N
C
N
263
N
C
N
264
N
C
N
265
N
C
N
266
N
O
N
267
N
H
N
268
N
H
N
269
N
H
N
270
N
H
N
271
N
H
N
272
N
H
N
273
N
H
N
274
N
H
N
275
N
H
N
276
N
H
N
277
N
H
N
278
N
H
N
279
N
H
N
280
N
N
N
281
S
C
N
282
N
C
N
283
N
O
N
284
N
C
N
285
N
C
N
286
N
C
N
287
N
C
N
288
N
N
N
289
N
O
N
290
N
H
N
291
N
H
N
292
N
H
N
293
N
H
N
294
N
H
N
295
N
H
N
296
N
H
N
297
N
H
N
298
N
H
N
299
N
H
N
300
N
H
N
301
N
H
N
302
N
H
N
303
N
H
N
304
N
H
N
305
N
N
N
306
S
C
N
307
N
C
N
308
N
O
N
309
N
C
N
310
N
C
N
311
N
S
N
312
N
C
N
313
N
O
N
314
N
H
N
315
N
H
N
316
N
H
N
317
N
H
N
318
N
H
N
319
N
H
N
320
N
H
N
321
N
H
N
322
N
H
N
323
N
H
N
324
N
H
N
325
N
N
N
326
S
C
N
327
N
C
N
328
N
O
N
329
N
C
Y
330
N
C
Y
331
N
C
Y
332
N
C
Y
333
N
C
Y
334
N
C
Y
335
N
C
N
336
N
O
N
337
N
H
N
338
N
H
N
339
N
H
N
340
N
H
N
341
N
H
N
342
N
H
N
343
N
H
N
344
N
H
N
345
N
H
N
346
N
H
N
347
N
H
N
348
N
N
N
349
S
C
N
350
N
C
N
351
N
O
N
352
N
C
N
353
N
C
N
354
N
C
N
355
N
O
N
356
N
H
N
357
N
H
N
358
N
H
N
359
N
H
N
360
N
H
N
361
N
H
N
362
N
H
N
363
N
H
N
364
N
H
N
365
N
N
N
366
S
C
N
367
N
C
N
368
N
O
N
369
N
C
N
370
N
O
N
371
N
O
N
372
N
H
N
373
N
H
N
374
N
H
N
375
N
H
N
376
N
H
N
377
N
H
N
378
N
H
N
379
N
N
N
380
S
C
N
381
N
C
N
382
N
O
N
383
R
C
N
384
N
O
N
385
N
C
N
386
N
O
N
387
N
H
N
388
N
H
N
389
N
H
N
390
N
H
N
391
N
H
N
392
N
H
N
393
N
H
N
394
N
H
N
395
N
H
N
396
N
N
N
397
S
C
N
398
N
C
N
399
N
O
N
400
N
C
Y
401
N
C
Y
402
N
C
Y
403
N
C
Y
404
N
N
Y
405
N
C
Y
406
N
C
Y
407
N
C
Y
408
N
C
Y
409
N
C
N
410
N
O
N
411
N
H
N
412
N
H
N
413
N
H
N
414
N
H
N
415
N
H
N
416
N
H
N
417
N
H
N
418
N
H
N
419
N
H
N
420
N
H
N
421
N
H
N
422
N
H
N
423
N
N
N
424
S
C
N
425
N
C
N
426
N
O
N
427
N
C
Y
428
N
C
Y
429
N
C
Y
430
N
C
Y
431
N
C
Y
432
N
C
Y
433
N
C
N
434
N
O
N
435
N
O
N
436
N
H
N
437
N
H
N
438
N
H
N
439
N
H
N
440
N
H
N
441
N
H
N
442
N
H
N
443
N
H
N
444
N
H
N
445
N
H
N
446
N
H
N
447
N
N
N
448
S
C
N
449
N
C
N
450
N
O
N
451
N
C
N
452
N
C
N
453
N
C
N
454
N
O
N
455
N
H
N
456
N
H
N
457
N
H
N
458
N
H
N
459
N
H
N
460
N
H
N
461
N
H
N
462
N
H
N
463
N
H
N
464
N
H
N
465
N
H
N
1
N
sing
N
2
N
sing
N
3
N
sing
N
4
N
sing
N
5
N
sing
N
6
N
sing
N
7
N
doub
N
8
N
doub
N
9
N
sing
Y
10
N
sing
Y
11
N
doub
Y
12
N
doub
Y
13
N
sing
Y
14
N
doub
N
15
N
sing
Y
16
N
sing
Y
17
N
sing
Y
18
N
doub
Y
19
N
doub
Y
20
N
sing
Y
21
N
doub
N
22
N
sing
Y
23
N
sing
N
24
N
sing
N
25
N
doub
N
26
N
sing
N
27
N
sing
Y
28
N
sing
Y
29
N
doub
Y
30
N
doub
Y
31
N
sing
Y
32
N
doub
Y
33
N
sing
N
34
N
sing
N
35
N
sing
N
36
N
sing
N
37
N
sing
N
38
N
sing
N
39
N
sing
N
40
N
sing
N
41
N
sing
N
42
N
sing
N
43
N
sing
N
44
N
sing
N
45
N
sing
N
46
N
sing
N
47
N
sing
N
48
N
sing
N
49
N
sing
N
50
N
sing
N
51
N
sing
N
52
N
sing
N
53
N
sing
N
54
N
sing
N
55
N
sing
N
56
N
sing
N
57
N
doub
N
58
N
sing
N
59
N
sing
N
60
N
sing
N
61
N
sing
N
62
N
sing
N
63
N
sing
N
64
N
sing
N
65
N
sing
N
66
N
sing
N
67
N
sing
N
68
N
sing
N
69
N
doub
N
70
N
sing
N
71
N
sing
N
72
N
sing
N
73
N
sing
N
74
N
sing
N
75
N
sing
N
76
N
sing
N
77
N
sing
N
78
N
sing
N
79
N
sing
N
80
N
sing
N
81
N
doub
N
82
N
sing
N
83
N
sing
N
84
N
sing
N
85
N
sing
N
86
N
sing
N
87
N
sing
N
88
N
sing
N
89
N
sing
N
90
N
sing
N
91
N
sing
N
92
N
sing
N
93
N
sing
N
94
N
sing
N
95
N
doub
N
96
N
sing
N
97
N
sing
N
98
N
sing
N
99
N
sing
N
100
N
sing
N
101
N
sing
N
102
N
sing
N
103
N
sing
N
104
N
sing
N
105
N
sing
N
106
N
sing
N
107
N
doub
N
108
N
sing
N
109
N
sing
N
110
N
sing
N
111
N
sing
N
112
N
doub
N
113
N
sing
N
114
N
sing
N
115
N
sing
N
116
N
sing
N
117
N
sing
N
118
N
sing
N
119
N
sing
N
120
N
sing
N
121
N
sing
N
122
N
sing
N
123
N
doub
N
124
N
sing
N
125
N
sing
N
126
N
sing
N
127
N
sing
N
128
N
doub
N
129
N
sing
N
130
N
sing
N
131
N
sing
N
132
N
sing
N
133
N
sing
N
134
N
sing
N
135
N
sing
N
136
N
sing
N
137
N
sing
N
138
N
doub
N
139
N
sing
N
140
N
sing
N
141
N
sing
N
142
N
sing
N
143
N
sing
N
144
N
sing
N
145
N
sing
N
146
N
sing
N
147
N
sing
N
148
N
sing
N
149
N
sing
N
150
N
sing
N
151
N
doub
N
152
N
sing
N
153
N
sing
N
154
N
sing
N
155
N
sing
N
156
N
sing
N
157
N
sing
N
158
N
sing
N
159
N
doub
N
160
N
sing
N
161
N
sing
N
162
N
sing
N
163
N
sing
N
164
N
sing
N
165
N
sing
N
166
N
sing
N
167
N
sing
N
168
N
sing
N
169
N
sing
N
170
N
doub
N
171
N
sing
N
172
N
sing
N
173
N
sing
N
174
N
sing
N
175
N
sing
N
176
N
sing
N
177
N
sing
N
178
N
doub
N
179
N
sing
N
180
N
sing
N
181
N
sing
N
182
N
sing
N
183
N
sing
N
184
N
sing
N
185
N
sing
N
186
N
sing
N
187
N
sing
N
188
N
doub
N
189
N
sing
N
190
N
sing
N
191
N
sing
N
192
N
sing
N
193
N
sing
N
194
N
sing
N
195
N
sing
N
196
N
sing
N
197
N
sing
N
198
N
sing
N
199
N
sing
N
200
N
sing
N
201
N
sing
N
202
N
sing
N
203
N
sing
N
204
N
sing
N
205
N
sing
N
206
N
sing
N
207
N
sing
N
208
N
sing
N
209
N
sing
N
210
N
doub
N
211
N
sing
N
212
N
sing
N
213
N
sing
N
214
N
sing
Y
215
N
sing
Y
216
N
doub
Y
217
N
doub
N
218
N
sing
Y
219
N
sing
N
220
N
sing
Y
221
N
sing
N
222
N
sing
N
223
N
sing
N
224
N
sing
N
225
N
sing
N
226
N
sing
N
227
N
sing
N
228
N
sing
N
229
N
sing
N
230
N
sing
N
231
N
sing
N
232
N
sing
N
233
N
doub
N
234
N
sing
N
235
N
sing
N
236
N
sing
N
237
N
sing
N
238
N
sing
N
239
N
sing
N
240
N
sing
N
241
N
sing
N
242
N
sing
N
243
N
sing
N
244
N
sing
N
245
N
sing
N
246
N
sing
N
247
N
sing
N
248
N
sing
N
249
N
sing
N
250
N
sing
N
251
N
sing
N
252
N
sing
N
253
N
sing
N
254
N
doub
N
255
N
sing
N
256
N
sing
N
257
N
sing
N
258
N
sing
N
259
N
sing
N
260
N
sing
N
261
N
sing
N
262
N
sing
N
263
N
sing
N
264
N
sing
N
265
N
sing
N
266
N
sing
N
267
N
sing
N
268
N
sing
N
269
N
sing
N
270
N
sing
N
271
N
sing
N
272
N
sing
N
273
N
sing
N
274
N
sing
N
275
N
doub
N
276
N
sing
N
277
N
sing
N
278
N
sing
N
279
N
sing
N
280
N
sing
N
281
N
sing
N
282
N
sing
N
283
N
sing
N
284
N
sing
N
285
N
sing
N
286
N
sing
N
287
N
sing
N
288
N
sing
N
289
N
sing
N
290
N
sing
N
291
N
sing
N
292
N
sing
N
293
N
sing
N
294
N
sing
N
295
N
sing
N
296
N
sing
N
297
N
sing
N
298
N
sing
N
299
N
doub
N
300
N
sing
N
301
N
sing
N
302
N
sing
N
303
N
sing
N
304
N
sing
N
305
N
sing
N
306
N
sing
N
307
N
sing
N
308
N
sing
N
309
N
sing
N
310
N
sing
N
311
N
sing
N
312
N
sing
N
313
N
sing
N
314
N
sing
N
315
N
sing
N
316
N
sing
N
317
N
sing
N
318
N
doub
N
319
N
sing
N
320
N
sing
N
321
N
sing
N
322
N
sing
Y
323
N
doub
Y
324
N
sing
Y
325
N
sing
N
326
N
sing
Y
327
N
doub
N
328
N
sing
Y
329
N
doub
N
330
N
sing
Y
331
N
sing
N
332
N
sing
N
333
N
sing
N
334
N
sing
N
335
N
sing
N
336
N
sing
N
337
N
sing
N
338
N
sing
N
339
N
sing
N
340
N
sing
N
341
N
doub
N
342
N
sing
N
343
N
sing
N
344
N
sing
N
345
N
sing
N
346
N
sing
N
347
N
sing
N
348
N
sing
N
349
N
sing
N
350
N
sing
N
351
N
sing
N
352
N
sing
N
353
N
sing
N
354
N
sing
N
355
N
sing
N
356
N
sing
N
357
N
sing
N
358
N
doub
N
359
N
sing
N
360
N
sing
N
361
N
sing
N
362
N
sing
N
363
N
sing
N
364
N
sing
N
365
N
sing
N
366
N
sing
N
367
N
sing
N
368
N
sing
N
369
N
sing
N
370
N
sing
N
371
N
doub
N
372
N
sing
N
373
N
sing
N
374
N
sing
N
375
N
sing
N
376
N
sing
N
377
N
sing
N
378
N
sing
N
379
N
sing
N
380
N
sing
N
381
N
sing
N
382
N
sing
N
383
N
sing
N
384
N
sing
N
385
N
sing
N
386
N
sing
N
387
N
doub
N
388
N
sing
N
389
N
sing
N
390
N
sing
N
391
N
sing
Y
392
N
doub
Y
393
N
sing
Y
394
N
sing
N
395
N
sing
Y
396
N
doub
Y
397
N
sing
Y
398
N
sing
N
399
N
sing
Y
400
N
sing
Y
401
N
doub
N
402
N
sing
Y
403
N
doub
N
404
N
sing
Y
405
N
sing
N
406
N
sing
N
407
N
sing
N
408
N
sing
N
409
N
sing
N
410
N
sing
N
411
N
sing
N
412
N
sing
N
413
N
sing
N
414
N
sing
N
415
N
doub
N
416
N
sing
N
417
N
sing
N
418
N
sing
N
419
N
sing
Y
420
N
doub
Y
421
N
sing
Y
422
N
sing
N
423
N
sing
Y
424
N
doub
N
425
N
sing
Y
426
N
doub
N
427
N
sing
Y
428
N
sing
N
429
N
sing
N
430
N
sing
N
431
N
sing
N
432
N
sing
N
433
N
sing
N
434
N
sing
N
435
N
sing
N
436
N
sing
N
437
N
sing
N
438
N
sing
N
439
N
doub
N
440
N
sing
N
441
N
sing
N
442
N
sing
N
443
N
sing
N
444
N
sing
N
445
N
sing
N
446
N
sing
N
447
N
sing
N
448
N
sing
N
449
N
sing
N
450
N
sing
US
J. Med. Chem.
JMCMAR
0151
1520-4804
55
9107
9119
10.1021/jm201724m
22489897
Discovery of novel potent and highly selective glycogen synthase kinase-3 beta (GSK3 beta ) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines.
2012
10.2210/pdb4acm/pdb
pdb_00004acm
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
100
1
CCD
2001-10-07
ADSC QUANTUM 315r
SI(311) MONOCHROMATOR
SINGLE WAVELENGTH
M
x-ray
1
0.98
1.0
ID29
ESRF
0.98
SYNCHROTRON
ESRF BEAMLINE ID29
ACETYLATION AT N-TERMINAL METHIONINE
34002.527
CYCLIN-DEPENDENT KINASE 2
2.7.11.22
1
man
polymer
92.094
GLYCEROL
2
syn
non-polymer
441.507
3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL]SULFAMOYL}PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
1
syn
non-polymer
18.015
water
183
nat
water
CELL DIVISION PROTEIN KINASE 2, P33 PROTEIN KINASE
no
yes
(ACE)MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENK
LYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVP
VRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPD
YKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL
XMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLV
FEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTY
THEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPS
FPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
HUMAN
sample
9606
HOMO SAPIENS
7108
SPODOPTERA FRUGIPERDA
SF21
BACULOVIRUS
1
2
39.7
NONE
8% PEG 3350, 0.1M HEPES PH 7.5, 0.05M AMMONIUM ACETATE
audit_author
citation
citation_author
chem_comp_atom
chem_comp_bond
database_2
pdbx_database_status
pdbx_initial_refinement_model
struct_conn
struct_site
repository
Initial release
Database references
Database references
Structure summary
Data collection
Database references
Derived calculations
Other
Refinement description
1
0
2012-05-16
1
1
2012-11-21
1
2
2018-02-14
1
3
2024-05-01
_audit_author.name
_citation.journal_abbrev
_citation.journal_id_ISSN
_citation.page_last
_citation.pdbx_database_id_DOI
_citation.title
_citation_author.name
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.status_code_sf
_struct_conn.pdbx_leaving_atom_flag
_struct_site.pdbx_auth_asym_id
_struct_site.pdbx_auth_comp_id
_struct_site.pdbx_auth_seq_id
CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325
CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM E2F
CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE -PHE-NH2
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2 ,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO] METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H- INDOL-2-ONE
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL-THIAZOL-5-YL) PYRIMIDIN-2-YL]-N'-HYDROXYIMINOFORMAMIDE
STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL-2'-OXO)BUTOXYPURINE
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN -(P-F-PHE)-NH2
CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL)AMINO] BENZENESULFONAMIDE
HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562
CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-1,2- DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO} BENZENESULFONAMIDE
CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX
DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
1ST PUBLICATION TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN 2ND PUBLICATION DESIGN, SYNTHESIS AND EVALUATION OF 2-METHYL- AND 2-AMINO-N-ARYL-4,5- DIHYDROTHIAZOLO (4,5-H)QUINAZOLIN-8-AMINES AS RING- CONSTRAINED 2-ANILINO-4-(THIAZOL-5-YL)PYRIMIDINE CDK INHIBITORS
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5B
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)- PYRIMIDIN-2-YL]-(3-NITRO-PHENYL)-AMINE
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4 -({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2 -OXO-2,3-DIHYDRO-1H-INDOLE
HUMAN CYCLIN-DEPENDENT KINASE 2
HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2 ,6,9-TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
P27(KIP1)/CYCLIN A/CDK2 COMPLEX
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5- YL)-PYRIMIDIN-2-YLAMINO]-PHENOL
CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN -DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE- BASED HYBRIDISATION
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H- L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR
HUMAN CYCLIN-DEPENDENT KINASE 2
APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5C
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2,4-DIMETHYL-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
HUMAN CYCLIN-DEPENDENT KINASE 2
CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX WITH PHOSPHO-CDK2
STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN -(P-F-PHE)-NH2
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN -2-YLAMINE
CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINEINHIBITOR
STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(4,3-H ) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, COMPOUND (S)-8B
CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) INCOMPLEX WITH PKF049-365
THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO- 1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID
THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A
THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS)
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN-232305
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N- METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO [5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL} METHANESULFONAMIDE
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN- 2-YLAMINE
CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A INCOMPLEX WITH THE INHIBITOR NU6271
CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR
CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5'-YL ]METHOXYPURINE
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL -9H-PURIN-2-YLAMINE AND MONOMERIC CDK2
CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE-REGULATORY PROTEIN CKSHS1
STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR
CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN -(M-CL-PHE)-NH2
HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN OXINDOLE INHIBITOR
PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA ( AT9283), A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL- 5-YL)PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE DIN-101312
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5- NITROSO-6-AMINOPYRIMIDINE INHIBITOR
CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH A NUCLEOSIDE INHIBITOR
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B]PYRIDAZINE
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDANT KINASE 2
CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE -(P-F-PHE)-NH2
TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN -DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE- BASED HYBRIDISATION
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN -DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE- BASED HYBRIDISATION
REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR
CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3- HYDROXYANILINO]-6,7- DIMETHOXYQUINAZOLINE
OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4-C PYRAZOLES : IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR EFFECTS
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)- PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE
HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL- 5-YL)PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL] METHOXYPURINE
CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 ( CDK2)IN COMPLEX WITH THE INHIBITOR H717
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2 -OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}- N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN -2-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE
CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR
PDBE
Y
PDBE
2011-12-16
REL
REL
1
A
O
HOH
2048
6.49
GOL
GLYCEROL
7YG
3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL]SULFAMOYL}PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
HOH
water
IN-HOUSE CDK2 MODEL
other
GOL
1300
2
GOL
GOL
1300
A
GOL
1301
2
GOL
GOL
1301
A
7YG
1302
3
7YG
7YG
1302
A
HOH
2001
4
HOH
HOH
2001
A
HOH
2002
4
HOH
HOH
2002
A
HOH
2003
4
HOH
HOH
2003
A
HOH
2004
4
HOH
HOH
2004
A
HOH
2005
4
HOH
HOH
2005
A
HOH
2006
4
HOH
HOH
2006
A
HOH
2007
4
HOH
HOH
2007
A
HOH
2008
4
HOH
HOH
2008
A
HOH
2009
4
HOH
HOH
2009
A
HOH
2010
4
HOH
HOH
2010
A
HOH
2011
4
HOH
HOH
2011
A
HOH
2012
4
HOH
HOH
2012
A
HOH
2013
4
HOH
HOH
2013
A
HOH
2014
4
HOH
HOH
2014
A
HOH
2015
4
HOH
HOH
2015
A
HOH
2016
4
HOH
HOH
2016
A
HOH
2017
4
HOH
HOH
2017
A
HOH
2018
4
HOH
HOH
2018
A
HOH
2019
4
HOH
HOH
2019
A
HOH
2020
4
HOH
HOH
2020
A
HOH
2021
4
HOH
HOH
2021
A
HOH
2022
4
HOH
HOH
2022
A
HOH
2023
4
HOH
HOH
2023
A
HOH
2024
4
HOH
HOH
2024
A
HOH
2025
4
HOH
HOH
2025
A
HOH
2026
4
HOH
HOH
2026
A
HOH
2027
4
HOH
HOH
2027
A
HOH
2028
4
HOH
HOH
2028
A
HOH
2029
4
HOH
HOH
2029
A
HOH
2030
4
HOH
HOH
2030
A
HOH
2031
4
HOH
HOH
2031
A
HOH
2032
4
HOH
HOH
2032
A
HOH
2033
4
HOH
HOH
2033
A
HOH
2034
4
HOH
HOH
2034
A
HOH
2035
4
HOH
HOH
2035
A
HOH
2036
4
HOH
HOH
2036
A
HOH
2037
4
HOH
HOH
2037
A
HOH
2038
4
HOH
HOH
2038
A
HOH
2039
4
HOH
HOH
2039
A
HOH
2040
4
HOH
HOH
2040
A
HOH
2041
4
HOH
HOH
2041
A
HOH
2042
4
HOH
HOH
2042
A
HOH
2043
4
HOH
HOH
2043
A
HOH
2044
4
HOH
HOH
2044
A
HOH
2045
4
HOH
HOH
2045
A
HOH
2046
4
HOH
HOH
2046
A
HOH
2047
4
HOH
HOH
2047
A
HOH
2048
4
HOH
HOH
2048
A
HOH
2049
4
HOH
HOH
2049
A
HOH
2050
4
HOH
HOH
2050
A
HOH
2051
4
HOH
HOH
2051
A
HOH
2052
4
HOH
HOH
2052
A
HOH
2053
4
HOH
HOH
2053
A
HOH
2054
4
HOH
HOH
2054
A
HOH
2055
4
HOH
HOH
2055
A
HOH
2056
4
HOH
HOH
2056
A
HOH
2057
4
HOH
HOH
2057
A
HOH
2058
4
HOH
HOH
2058
A
HOH
2059
4
HOH
HOH
2059
A
HOH
2060
4
HOH
HOH
2060
A
HOH
2061
4
HOH
HOH
2061
A
HOH
2062
4
HOH
HOH
2062
A
HOH
2063
4
HOH
HOH
2063
A
HOH
2064
4
HOH
HOH
2064
A
HOH
2065
4
HOH
HOH
2065
A
HOH
2066
4
HOH
HOH
2066
A
HOH
2067
4
HOH
HOH
2067
A
HOH
2068
4
HOH
HOH
2068
A
HOH
2069
4
HOH
HOH
2069
A
HOH
2070
4
HOH
HOH
2070
A
HOH
2071
4
HOH
HOH
2071
A
HOH
2072
4
HOH
HOH
2072
A
HOH
2073
4
HOH
HOH
2073
A
HOH
2074
4
HOH
HOH
2074
A
HOH
2075
4
HOH
HOH
2075
A
HOH
2076
4
HOH
HOH
2076
A
HOH
2077
4
HOH
HOH
2077
A
HOH
2078
4
HOH
HOH
2078
A
HOH
2079
4
HOH
HOH
2079
A
HOH
2080
4
HOH
HOH
2080
A
HOH
2081
4
HOH
HOH
2081
A
HOH
2082
4
HOH
HOH
2082
A
HOH
2083
4
HOH
HOH
2083
A
HOH
2084
4
HOH
HOH
2084
A
HOH
2085
4
HOH
HOH
2085
A
HOH
2086
4
HOH
HOH
2086
A
HOH
2087
4
HOH
HOH
2087
A
HOH
2088
4
HOH
HOH
2088
A
HOH
2089
4
HOH
HOH
2089
A
HOH
2090
4
HOH
HOH
2090
A
HOH
2091
4
HOH
HOH
2091
A
HOH
2092
4
HOH
HOH
2092
A
HOH
2093
4
HOH
HOH
2093
A
HOH
2094
4
HOH
HOH
2094
A
HOH
2095
4
HOH
HOH
2095
A
HOH
2096
4
HOH
HOH
2096
A
HOH
2097
4
HOH
HOH
2097
A
HOH
2098
4
HOH
HOH
2098
A
HOH
2099
4
HOH
HOH
2099
A
HOH
2100
4
HOH
HOH
2100
A
HOH
2101
4
HOH
HOH
2101
A
HOH
2102
4
HOH
HOH
2102
A
HOH
2103
4
HOH
HOH
2103
A
HOH
2104
4
HOH
HOH
2104
A
HOH
2105
4
HOH
HOH
2105
A
HOH
2106
4
HOH
HOH
2106
A
HOH
2107
4
HOH
HOH
2107
A
HOH
2108
4
HOH
HOH
2108
A
HOH
2109
4
HOH
HOH
2109
A
HOH
2110
4
HOH
HOH
2110
A
HOH
2111
4
HOH
HOH
2111
A
HOH
2112
4
HOH
HOH
2112
A
HOH
2113
4
HOH
HOH
2113
A
HOH
2114
4
HOH
HOH
2114
A
HOH
2115
4
HOH
HOH
2115
A
HOH
2116
4
HOH
HOH
2116
A
HOH
2117
4
HOH
HOH
2117
A
HOH
2118
4
HOH
HOH
2118
A
HOH
2119
4
HOH
HOH
2119
A
HOH
2120
4
HOH
HOH
2120
A
HOH
2121
4
HOH
HOH
2121
A
HOH
2122
4
HOH
HOH
2122
A
HOH
2123
4
HOH
HOH
2123
A
HOH
2124
4
HOH
HOH
2124
A
HOH
2125
4
HOH
HOH
2125
A
HOH
2126
4
HOH
HOH
2126
A
HOH
2127
4
HOH
HOH
2127
A
HOH
2128
4
HOH
HOH
2128
A
HOH
2129
4
HOH
HOH
2129
A
HOH
2130
4
HOH
HOH
2130
A
HOH
2131
4
HOH
HOH
2131
A
HOH
2132
4
HOH
HOH
2132
A
HOH
2133
4
HOH
HOH
2133
A
HOH
2134
4
HOH
HOH
2134
A
HOH
2135
4
HOH
HOH
2135
A
HOH
2136
4
HOH
HOH
2136
A
HOH
2137
4
HOH
HOH
2137
A
HOH
2138
4
HOH
HOH
2138
A
HOH
2139
4
HOH
HOH
2139
A
HOH
2140
4
HOH
HOH
2140
A
HOH
2141
4
HOH
HOH
2141
A
HOH
2142
4
HOH
HOH
2142
A
HOH
2143
4
HOH
HOH
2143
A
HOH
2144
4
HOH
HOH
2144
A
HOH
2145
4
HOH
HOH
2145
A
HOH
2146
4
HOH
HOH
2146
A
HOH
2147
4
HOH
HOH
2147
A
HOH
2148
4
HOH
HOH
2148
A
HOH
2149
4
HOH
HOH
2149
A
HOH
2150
4
HOH
HOH
2150
A
HOH
2151
4
HOH
HOH
2151
A
HOH
2152
4
HOH
HOH
2152
A
HOH
2153
4
HOH
HOH
2153
A
HOH
2154
4
HOH
HOH
2154
A
HOH
2155
4
HOH
HOH
2155
A
HOH
2156
4
HOH
HOH
2156
A
HOH
2157
4
HOH
HOH
2157
A
HOH
2158
4
HOH
HOH
2158
A
HOH
2159
4
HOH
HOH
2159
A
HOH
2160
4
HOH
HOH
2160
A
HOH
2161
4
HOH
HOH
2161
A
HOH
2162
4
HOH
HOH
2162
A
HOH
2163
4
HOH
HOH
2163
A
HOH
2164
4
HOH
HOH
2164
A
HOH
2165
4
HOH
HOH
2165
A
HOH
2166
4
HOH
HOH
2166
A
HOH
2167
4
HOH
HOH
2167
A
HOH
2168
4
HOH
HOH
2168
A
HOH
2169
4
HOH
HOH
2169
A
HOH
2170
4
HOH
HOH
2170
A
HOH
2171
4
HOH
HOH
2171
A
HOH
2172
4
HOH
HOH
2172
A
HOH
2173
4
HOH
HOH
2173
A
HOH
2174
4
HOH
HOH
2174
A
HOH
2175
4
HOH
HOH
2175
A
HOH
2176
4
HOH
HOH
2176
A
HOH
2177
4
HOH
HOH
2177
A
HOH
2178
4
HOH
HOH
2178
A
HOH
2179
4
HOH
HOH
2179
A
HOH
2180
4
HOH
HOH
2180
A
HOH
2181
4
HOH
HOH
2181
A
HOH
2182
4
HOH
HOH
2182
A
HOH
2183
4
HOH
HOH
2183
A
ACE
0
n
1
ACE
0
A
MET
1
n
2
MET
1
A
GLU
2
n
3
GLU
2
A
ASN
3
n
4
ASN
3
A
PHE
4
n
5
PHE
4
A
GLN
5
n
6
GLN
5
A
LYS
6
n
7
LYS
6
A
VAL
7
n
8
VAL
7
A
GLU
8
n
9
GLU
8
A
LYS
9
n
10
LYS
9
A
ILE
10
n
11
ILE
10
A
GLY
11
n
12
GLY
11
A
GLU
12
n
13
GLU
12
A
GLY
13
n
14
GLY
13
A
THR
14
n
15
THR
14
A
TYR
15
n
16
TYR
15
A
GLY
16
n
17
GLY
16
A
VAL
17
n
18
VAL
17
A
VAL
18
n
19
VAL
18
A
TYR
19
n
20
TYR
19
A
LYS
20
n
21
LYS
20
A
ALA
21
n
22
ALA
21
A
ARG
22
n
23
ARG
22
A
ASN
23
n
24
ASN
23
A
LYS
24
n
25
LYS
24
A
LEU
25
n
26
LEU
25
A
THR
26
n
27
THR
26
A
GLY
27
n
28
GLY
27
A
GLU
28
n
29
GLU
28
A
VAL
29
n
30
VAL
29
A
VAL
30
n
31
VAL
30
A
ALA
31
n
32
ALA
31
A
LEU
32
n
33
LEU
32
A
LYS
33
n
34
LYS
33
A
LYS
34
n
35
LYS
34
A
ILE
35
n
36
ILE
35
A
ARG
36
n
37
ARG
36
A
n
38
37
A
n
39
38
A
n
40
39
A
n
41
40
A
n
42
41
A
n
43
42
A
n
44
43
A
VAL
44
n
45
VAL
44
A
PRO
45
n
46
PRO
45
A
SER
46
n
47
SER
46
A
THR
47
n
48
THR
47
A
ALA
48
n
49
ALA
48
A
ILE
49
n
50
ILE
49
A
ARG
50
n
51
ARG
50
A
GLU
51
n
52
GLU
51
A
ILE
52
n
53
ILE
52
A
SER
53
n
54
SER
53
A
LEU
54
n
55
LEU
54
A
LEU
55
n
56
LEU
55
A
LYS
56
n
57
LYS
56
A
GLU
57
n
58
GLU
57
A
LEU
58
n
59
LEU
58
A
ASN
59
n
60
ASN
59
A
HIS
60
n
61
HIS
60
A
PRO
61
n
62
PRO
61
A
ASN
62
n
63
ASN
62
A
ILE
63
n
64
ILE
63
A
VAL
64
n
65
VAL
64
A
LYS
65
n
66
LYS
65
A
LEU
66
n
67
LEU
66
A
LEU
67
n
68
LEU
67
A
ASP
68
n
69
ASP
68
A
VAL
69
n
70
VAL
69
A
ILE
70
n
71
ILE
70
A
HIS
71
n
72
HIS
71
A
THR
72
n
73
THR
72
A
n
74
73
A
n
75
74
A
LYS
75
n
76
LYS
75
A
LEU
76
n
77
LEU
76
A
TYR
77
n
78
TYR
77
A
LEU
78
n
79
LEU
78
A
VAL
79
n
80
VAL
79
A
PHE
80
n
81
PHE
80
A
GLU
81
n
82
GLU
81
A
PHE
82
n
83
PHE
82
A
LEU
83
n
84
LEU
83
A
HIS
84
n
85
HIS
84
A
GLN
85
n
86
GLN
85
A
ASP
86
n
87
ASP
86
A
LEU
87
n
88
LEU
87
A
LYS
88
n
89
LYS
88
A
LYS
89
n
90
LYS
89
A
PHE
90
n
91
PHE
90
A
MET
91
n
92
MET
91
A
ASP
92
n
93
ASP
92
A
ALA
93
n
94
ALA
93
A
SER
94
n
95
SER
94
A
ALA
95
n
96
ALA
95
A
LEU
96
n
97
LEU
96
A
THR
97
n
98
THR
97
A
GLY
98
n
99
GLY
98
A
ILE
99
n
100
ILE
99
A
PRO
100
n
101
PRO
100
A
LEU
101
n
102
LEU
101
A
PRO
102
n
103
PRO
102
A
LEU
103
n
104
LEU
103
A
ILE
104
n
105
ILE
104
A
LYS
105
n
106
LYS
105
A
SER
106
n
107
SER
106
A
TYR
107
n
108
TYR
107
A
LEU
108
n
109
LEU
108
A
PHE
109
n
110
PHE
109
A
GLN
110
n
111
GLN
110
A
LEU
111
n
112
LEU
111
A
LEU
112
n
113
LEU
112
A
GLN
113
n
114
GLN
113
A
GLY
114
n
115
GLY
114
A
LEU
115
n
116
LEU
115
A
ALA
116
n
117
ALA
116
A
PHE
117
n
118
PHE
117
A
CYS
118
n
119
CYS
118
A
HIS
119
n
120
HIS
119
A
SER
120
n
121
SER
120
A
HIS
121
n
122
HIS
121
A
ARG
122
n
123
ARG
122
A
VAL
123
n
124
VAL
123
A
LEU
124
n
125
LEU
124
A
HIS
125
n
126
HIS
125
A
ARG
126
n
127
ARG
126
A
ASP
127
n
128
ASP
127
A
LEU
128
n
129
LEU
128
A
LYS
129
n
130
LYS
129
A
PRO
130
n
131
PRO
130
A
GLN
131
n
132
GLN
131
A
ASN
132
n
133
ASN
132
A
LEU
133
n
134
LEU
133
A
LEU
134
n
135
LEU
134
A
ILE
135
n
136
ILE
135
A
ASN
136
n
137
ASN
136
A
THR
137
n
138
THR
137
A
GLU
138
n
139
GLU
138
A
GLY
139
n
140
GLY
139
A
ALA
140
n
141
ALA
140
A
ILE
141
n
142
ILE
141
A
LYS
142
n
143
LYS
142
A
LEU
143
n
144
LEU
143
A
ALA
144
n
145
ALA
144
A
ASP
145
n
146
ASP
145
A
PHE
146
n
147
PHE
146
A
GLY
147
n
148
GLY
147
A
LEU
148
n
149
LEU
148
A
ALA
149
n
150
ALA
149
A
ARG
150
n
151
ARG
150
A
n
152
151
A
n
153
152
A
n
154
153
A
n
155
154
A
n
156
155
A
n
157
156
A
n
158
157
A
n
159
158
A
n
160
159
A
n
161
160
A
n
162
161
A
n
163
162
A
VAL
163
n
164
VAL
163
A
VAL
164
n
165
VAL
164
A
THR
165
n
166
THR
165
A
LEU
166
n
167
LEU
166
A
TRP
167
n
168
TRP
167
A
TYR
168
n
169
TYR
168
A
ARG
169
n
170
ARG
169
A
ALA
170
n
171
ALA
170
A
PRO
171
n
172
PRO
171
A
GLU
172
n
173
GLU
172
A
ILE
173
n
174
ILE
173
A
LEU
174
n
175
LEU
174
A
LEU
175
n
176
LEU
175
A
GLY
176
n
177
GLY
176
A
CYS
177
n
178
CYS
177
A
LYS
178
n
179
LYS
178
A
TYR
179
n
180
TYR
179
A
TYR
180
n
181
TYR
180
A
SER
181
n
182
SER
181
A
THR
182
n
183
THR
182
A
ALA
183
n
184
ALA
183
A
VAL
184
n
185
VAL
184
A
ASP
185
n
186
ASP
185
A
ILE
186
n
187
ILE
186
A
TRP
187
n
188
TRP
187
A
SER
188
n
189
SER
188
A
LEU
189
n
190
LEU
189
A
GLY
190
n
191
GLY
190
A
CYS
191
n
192
CYS
191
A
ILE
192
n
193
ILE
192
A
PHE
193
n
194
PHE
193
A
ALA
194
n
195
ALA
194
A
GLU
195
n
196
GLU
195
A
MET
196
n
197
MET
196
A
VAL
197
n
198
VAL
197
A
THR
198
n
199
THR
198
A
ARG
199
n
200
ARG
199
A
ARG
200
n
201
ARG
200
A
ALA
201
n
202
ALA
201
A
LEU
202
n
203
LEU
202
A
PHE
203
n
204
PHE
203
A
PRO
204
n
205
PRO
204
A
GLY
205
n
206
GLY
205
A
ASP
206
n
207
ASP
206
A
SER
207
n
208
SER
207
A
GLU
208
n
209
GLU
208
A
ILE
209
n
210
ILE
209
A
ASP
210
n
211
ASP
210
A
GLN
211
n
212
GLN
211
A
LEU
212
n
213
LEU
212
A
PHE
213
n
214
PHE
213
A
ARG
214
n
215
ARG
214
A
ILE
215
n
216
ILE
215
A
PHE
216
n
217
PHE
216
A
ARG
217
n
218
ARG
217
A
THR
218
n
219
THR
218
A
LEU
219
n
220
LEU
219
A
GLY
220
n
221
GLY
220
A
THR
221
n
222
THR
221
A
PRO
222
n
223
PRO
222
A
ASP
223
n
224
ASP
223
A
GLU
224
n
225
GLU
224
A
VAL
225
n
226
VAL
225
A
VAL
226
n
227
VAL
226
A
TRP
227
n
228
TRP
227
A
PRO
228
n
229
PRO
228
A
GLY
229
n
230
GLY
229
A
VAL
230
n
231
VAL
230
A
THR
231
n
232
THR
231
A
SER
232
n
233
SER
232
A
MET
233
n
234
MET
233
A
PRO
234
n
235
PRO
234
A
ASP
235
n
236
ASP
235
A
TYR
236
n
237
TYR
236
A
LYS
237
n
238
LYS
237
A
PRO
238
n
239
PRO
238
A
SER
239
n
240
SER
239
A
PHE
240
n
241
PHE
240
A
PRO
241
n
242
PRO
241
A
LYS
242
n
243
LYS
242
A
TRP
243
n
244
TRP
243
A
ALA
244
n
245
ALA
244
A
ARG
245
n
246
ARG
245
A
GLN
246
n
247
GLN
246
A
ASP
247
n
248
ASP
247
A
PHE
248
n
249
PHE
248
A
SER
249
n
250
SER
249
A
LYS
250
n
251
LYS
250
A
VAL
251
n
252
VAL
251
A
VAL
252
n
253
VAL
252
A
PRO
253
n
254
PRO
253
A
PRO
254
n
255
PRO
254
A
LEU
255
n
256
LEU
255
A
ASP
256
n
257
ASP
256
A
GLU
257
n
258
GLU
257
A
ASP
258
n
259
ASP
258
A
GLY
259
n
260
GLY
259
A
ARG
260
n
261
ARG
260
A
SER
261
n
262
SER
261
A
LEU
262
n
263
LEU
262
A
LEU
263
n
264
LEU
263
A
SER
264
n
265
SER
264
A
GLN
265
n
266
GLN
265
A
MET
266
n
267
MET
266
A
LEU
267
n
268
LEU
267
A
HIS
268
n
269
HIS
268
A
TYR
269
n
270
TYR
269
A
ASP
270
n
271
ASP
270
A
PRO
271
n
272
PRO
271
A
ASN
272
n
273
ASN
272
A
LYS
273
n
274
LYS
273
A
ARG
274
n
275
ARG
274
A
ILE
275
n
276
ILE
275
A
SER
276
n
277
SER
276
A
ALA
277
n
278
ALA
277
A
LYS
278
n
279
LYS
278
A
ALA
279
n
280
ALA
279
A
ALA
280
n
281
ALA
280
A
LEU
281
n
282
LEU
281
A
ALA
282
n
283
ALA
282
A
HIS
283
n
284
HIS
283
A
PRO
284
n
285
PRO
284
A
PHE
285
n
286
PHE
285
A
PHE
286
n
287
PHE
286
A
GLN
287
n
288
GLN
287
A
ASP
288
n
289
ASP
288
A
VAL
289
n
290
VAL
289
A
THR
290
n
291
THR
290
A
LYS
291
n
292
LYS
291
A
PRO
292
n
293
PRO
292
A
VAL
293
n
294
VAL
293
A
PRO
294
n
295
PRO
294
A
HIS
295
n
296
HIS
295
A
LEU
296
n
297
LEU
296
A
ARG
297
n
298
ARG
297
A
LEU
298
n
299
LEU
298
A
1.1852
0.3106
-0.1712
0.3579
-0.0740
2.0669
0.0337
0.0805
0.0450
0.0074
-0.0063
0.0962
0.0126
-0.0284
-0.0274
-0.0614
-0.0011
-0.0002
-0.0812
0.0156
-0.0634
refined
2.8543
30.8176
22.7325
X-RAY DIFFRACTION
X-RAY DIFFRACTION
1
CHAIN A
author_and_software_defined_assembly
PISA
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
GLY
13
A
N
GLY
14
A
O
GLY
16
A
O
GLY
17
A
N
ALA
21
A
N
ALA
22
A
O
VAL
30
A
O
VAL
31
A
N
ILE
35
A
N
ILE
36
A
O
LEU
76
A
O
LEU
77
A
O
VAL
79
A
O
VAL
80
A
N
LEU
67
A
N
LEU
68
A
N
GLN
85
A
N
GLN
86
A
O
ILE
135
A
O
ILE
136
A
N
LEU
134
A
N
LEU
135
A
O
LYS
142
A
O
LYS
143
1
A
CG
GLU
2
A
CG
GLU
3
1
Y
1
A
CD
GLU
2
A
CD
GLU
3
1
Y
1
A
OE1
GLU
2
A
OE1
GLU
3
1
Y
1
A
OE2
GLU
2
A
OE2
GLU
3
1
Y
1
A
CD
GLN
5
A
CD
GLN
6
1
Y
1
A
OE1
GLN
5
A
OE1
GLN
6
1
Y
1
A
NE2
GLN
5
A
NE2
GLN
6
1
Y
1
A
CD
LYS
9
A
CD
LYS
10
1
Y
1
A
CE
LYS
9
A
CE
LYS
10
1
Y
1
A
NZ
LYS
9
A
NZ
LYS
10
1
Y
1
A
CG
GLU
12
A
CG
GLU
13
1
Y
1
A
CD
GLU
12
A
CD
GLU
13
1
Y
1
A
OE1
GLU
12
A
OE1
GLU
13
1
Y
1
A
OE2
GLU
12
A
OE2
GLU
13
1
Y
1
A
CG
TYR
15
A
CG
TYR
16
1
Y
1
A
CD1
TYR
15
A
CD1
TYR
16
1
Y
1
A
CD2
TYR
15
A
CD2
TYR
16
1
Y
1
A
CE1
TYR
15
A
CE1
TYR
16
1
Y
1
A
CE2
TYR
15
A
CE2
TYR
16
1
Y
1
A
CZ
TYR
15
A
CZ
TYR
16
1
Y
1
A
OH
TYR
15
A
OH
TYR
16
1
Y
1
A
CG
LEU
25
A
CG
LEU
26
1
Y
1
A
CD1
LEU
25
A
CD1
LEU
26
1
Y
1
A
CD2
LEU
25
A
CD2
LEU
26
1
Y
1
A
CG
LYS
34
A
CG
LYS
35
1
Y
1
A
CD
LYS
34
A
CD
LYS
35
1
Y
1
A
CE
LYS
34
A
CE
LYS
35
1
Y
1
A
NZ
LYS
34
A
NZ
LYS
35
1
Y
1
A
CG
ARG
36
A
CG
ARG
37
1
Y
1
A
CD
ARG
36
A
CD
ARG
37
1
Y
1
A
NE
ARG
36
A
NE
ARG
37
1
Y
1
A
CZ
ARG
36
A
CZ
ARG
37
1
Y
1
A
NH1
ARG
36
A
NH1
ARG
37
1
Y
1
A
NH2
ARG
36
A
NH2
ARG
37
1
Y
1
A
CG
ARG
50
A
CG
ARG
51
1
Y
1
A
CD
ARG
50
A
CD
ARG
51
1
Y
1
A
NE
ARG
50
A
NE
ARG
51
1
Y
1
A
CZ
ARG
50
A
CZ
ARG
51
1
Y
1
A
NH1
ARG
50
A
NH1
ARG
51
1
Y
1
A
NH2
ARG
50
A
NH2
ARG
51
1
Y
1
A
CG
GLU
51
A
CG
GLU
52
1
Y
1
A
CD
GLU
51
A
CD
GLU
52
1
Y
1
A
OE1
GLU
51
A
OE1
GLU
52
1
Y
1
A
OE2
GLU
51
A
OE2
GLU
52
1
Y
1
A
CG
LYS
75
A
CG
LYS
76
1
Y
1
A
CD
LYS
75
A
CD
LYS
76
1
Y
1
A
CE
LYS
75
A
CE
LYS
76
1
Y
1
A
NZ
LYS
75
A
NZ
LYS
76
1
Y
1
A
CG
LEU
96
A
CG
LEU
97
1
Y
1
A
CD1
LEU
96
A
CD1
LEU
97
1
Y
1
A
CD2
LEU
96
A
CD2
LEU
97
1
Y
1
A
CG
LYS
178
A
CG
LYS
179
1
Y
1
A
CD
LYS
178
A
CD
LYS
179
1
Y
1
A
CE
LYS
178
A
CE
LYS
179
1
Y
1
A
NZ
LYS
178
A
NZ
LYS
179
1
Y
1
A
CD
ARG
217
A
CD
ARG
218
1
Y
1
A
NE
ARG
217
A
NE
ARG
218
1
Y
1
A
CZ
ARG
217
A
CZ
ARG
218
1
Y
1
A
NH1
ARG
217
A
NH1
ARG
218
1
Y
1
A
NH2
ARG
217
A
NH2
ARG
218
1
Y
1
A
CG
LYS
273
A
CG
LYS
274
1
Y
1
A
CD
LYS
273
A
CD
LYS
274
1
Y
1
A
CE
LYS
273
A
CE
LYS
274
1
Y
1
A
NZ
LYS
273
A
NZ
LYS
274
1
Y
1
A
CG
LYS
278
A
CG
LYS
279
1
Y
1
A
CD
LYS
278
A
CD
LYS
279
1
Y
1
A
CE
LYS
278
A
CE
LYS
279
1
Y
1
A
NZ
LYS
278
A
NZ
LYS
279
1
Y
1
A
CG
ARG
297
A
CG
ARG
298
1
Y
1
A
CD
ARG
297
A
CD
ARG
298
1
Y
1
A
NE
ARG
297
A
NE
ARG
298
1
Y
1
A
CZ
ARG
297
A
CZ
ARG
298
1
Y
1
A
NH1
ARG
297
A
NH1
ARG
298
1
Y
1
A
NH2
ARG
297
A
NH2
ARG
298
1
Y
1
A
LEU
37
A
LEU
38
1
Y
1
A
ASP
38
A
ASP
39
1
Y
1
A
THR
39
A
THR
40
1
Y
1
A
GLU
40
A
GLU
41
1
Y
1
A
THR
41
A
THR
42
1
Y
1
A
GLU
42
A
GLU
43
1
Y
1
A
GLY
43
A
GLY
44
1
Y
1
A
GLU
73
A
GLU
74
1
Y
1
A
ASN
74
A
ASN
75
1
Y
1
A
ALA
151
A
ALA
152
1
Y
1
A
PHE
152
A
PHE
153
1
Y
1
A
GLY
153
A
GLY
154
1
Y
1
A
VAL
154
A
VAL
155
1
Y
1
A
PRO
155
A
PRO
156
1
Y
1
A
VAL
156
A
VAL
157
1
Y
1
A
ARG
157
A
ARG
158
1
Y
1
A
THR
158
A
THR
159
1
Y
1
A
TYR
159
A
TYR
160
1
Y
1
A
THR
160
A
THR
161
1
Y
1
A
HIS
161
A
HIS
162
1
Y
1
A
GLU
162
A
GLU
163
1
Y
1
12.43
1.60
122.70
135.13
A
A
A
O
C
N
ACE
ACE
MET
0
0
1
Y
1
A
ARG
126
80.89
-15.76
1
A
ASP
127
-140.45
43.47
1
A
TYR
179
-114.69
63.64
34.34
3.6510
0.0000
0.0000
-9.4468
0.0000
5.7958
0.9389
0.9276
IDEAL-DIST CONTACT TERM CONTACT SETUP. ALL ATOMS HAVE CCP4 ATOM TYPE FROM LIBRARY
0.2184
0.1836
0.1854
1.63
29.87
1333
26843
4.97
76.11
0.126
RANDOM
1
THROUGHOUT
0.0
MOLECULAR REPLACEMENT
0.130
0.120
0.118
IN-HOUSE CDK2 MODEL
0.214
1.63
29.87
183
2387
43
0
2161
0.010
2384
HARMONIC
2.00
1.03
3263
HARMONIC
2.00
785
SINUSOIDAL
2.00
42
HARMONIC
2.00
348
HARMONIC
5.00
2384
HARMONIC
20.00
3.10
18.69
303
SEMIHARMONIC
5.00
14
HARMONIC
1.00
3016
SEMIHARMONIC
4.00
0.2531
0.3083
0.3071
1.70
8
353
361
13
2.22
76.11
26.59
1.63
29.88
4ACM
26915
2.0
0.06
1
8.80
5.4
74.3
0.35
1.63
1.71
2.20
1
1.4
8.9
refinement
BUSTER
2.11.2
data reduction
MOSFLM
data scaling
SCALA
phasing
AMoRE
CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL]SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
1
N
N
2
N
N
2
N
N
3
N
N
4
N
N
A
PRO
45
A
PRO
46
HELX_P
A
LYS
56
A
LYS
57
1
1
12
A
LEU
87
A
LEU
88
HELX_P
A
SER
94
A
SER
95
1
2
8
A
PRO
100
A
PRO
101
HELX_P
A
HIS
121
A
HIS
122
1
3
22
A
LYS
129
A
LYS
130
HELX_P
A
GLN
131
A
GLN
132
5
4
3
A
ALA
170
A
ALA
171
HELX_P
A
LEU
175
A
LEU
176
1
5
6
A
THR
182
A
THR
183
HELX_P
A
ARG
199
A
ARG
200
1
6
18
A
SER
207
A
SER
208
HELX_P
A
GLY
220
A
GLY
221
1
7
14
A
GLY
229
A
GLY
230
HELX_P
A
MET
233
A
MET
234
5
8
5
A
ASP
247
A
ASP
248
HELX_P
A
VAL
252
A
VAL
253
1
9
6
A
ASP
256
A
ASP
257
HELX_P
A
LEU
267
A
LEU
268
1
10
12
A
SER
276
A
SER
277
HELX_P
A
ALA
282
A
ALA
283
1
11
7
A
HIS
283
A
HIS
284
HELX_P
A
GLN
287
A
GLN
288
5
12
5
covale
1.399
both
A
ACE
0
A
C
ACE
1
1_555
A
MET
1
A
N
MET
2
1_555
TRANSFERASE
MITOSIS, CELL CYCLE, TRANSFERASE, SERINE/THREONINE- PROTEIN KINASE, ATP-BINDING, CELL DIVISION, NUCLEOTIDE-BINDING
A
PRO
253
A
PRO
254
1
A
PRO
254
A
PRO
255
7.61
CDK2_HUMAN
UNP
1
P24941
1
298
4ACM
1
298
P24941
A
1
2
299
5
3
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
A
PHE
4
A
PHE
5
A
GLY
13
A
GLY
14
A
GLY
16
A
GLY
17
A
ASN
23
A
ASN
24
A
VAL
29
A
VAL
30
A
ILE
35
A
ILE
36
A
LEU
76
A
LEU
77
A
GLU
81
A
GLU
82
A
LEU
66
A
LEU
67
A
HIS
71
A
HIS
72
A
GLN
85
A
GLN
86
A
ASP
86
A
ASP
87
A
LEU
133
A
LEU
134
A
ILE
135
A
ILE
136
A
ILE
141
A
ILE
142
A
LEU
143
A
LEU
144
BINDING SITE FOR RESIDUE GOL A 1300
A
GOL
1300
Software
6
BINDING SITE FOR RESIDUE GOL A 1301
A
GOL
1301
Software
3
BINDING SITE FOR RESIDUE 7YG A 1302
A
7YG
1302
Software
15
A
TRP
167
A
TRP
168
6
1_555
A
ARG
200
A
ARG
201
6
1_555
A
ALA
201
A
ALA
202
6
1_555
A
PRO
204
A
PRO
205
6
1_555
A
HOH
2016
E
HOH
6
3_545
A
HOH
2106
E
HOH
6
1_555
A
PHE
109
A
PHE
110
3
1_555
A
PHE
286
A
PHE
287
3
1_555
A
VAL
289
A
VAL
290
3
1_555
A
ILE
10
A
ILE
11
15
1_555
A
VAL
18
A
VAL
19
15
1_555
A
ALA
31
A
ALA
32
15
1_555
A
LYS
33
A
LYS
34
15
1_555
A
VAL
64
A
VAL
65
15
1_555
A
GLU
81
A
GLU
82
15
1_555
A
PHE
82
A
PHE
83
15
1_555
A
LEU
83
A
LEU
84
15
1_555
A
HIS
84
A
HIS
85
15
1_555
A
GLN
85
A
GLN
86
15
1_555
A
ASP
86
A
ASP
87
15
1_555
A
LYS
89
A
LYS
90
15
1_555
A
GLN
131
A
GLN
132
15
1_555
A
LEU
134
A
LEU
135
15
1_555
A
ASP
145
A
ASP
146
15
1_555
19
P 21 21 21